ArticleFuture oncology (London, England)2024

The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients.

Dilek Çağlayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.